A clinical stage cardiovascular company is gearing up for market. They need an all-encompassing team to support their venture.

A breath of fresh air.

InCarda Therapeutics

InCarda Therapeutics, a biopharmaceutical company out of Palo Alto, CA, discovered a faster and more-effective way to treat cardiovascular disease: via the inhalation route. This novel approach brings a huge advantage – it offers a lower dose, with more control, ensuring the effects are extremely targeted and patients are not over-exposed to the drug.


Partner Since

Life Sciences

Bay Area, CA

Communicating care.

When we met, InCarda was riding strong momentum from a Series A round. They were embarking on human trials and needed a communications strategy to reach prospective subjects who were in need of a better solution.

In conjunction, planning was underway for a Series B to engage a wider audience of investors, Key Opinion Leaders (KOLs) and early adopters.

Together we set out on key initiatives…

Key Initiatives Included:

Developed authentic brand and value proposition to attract investors.


Key Initiatives Included:

Partner with commercial & regulatory team on product packaging branding.


Key Initiatives Included:

Direct engagement with executive team for culture-building activities for recruitment and retention.


Key Initiatives Included:

Enhance digital footprint for US and OUS market engagement.


Key Initiatives Included:

Align with regulatory team in developing patient and physician facing Instructions for Use.


“I cannot say enough good things about the experience working with Howbridge. The value of our partnership goes well beyond tactical elements.

I liked the way they became a strategic partner for InCarda – as a startup, we needed a more integrated, comprehensive approach. I’ve already recommended Howbridge to several people, and the team is currently working with many of my parent companies.”

– Grace E. Colón, Ph.D., Board Member & Former Chief Executive Officer, InCarda Therapeutics

A brand built for international growth.

Through our strategic insight, InCarda achieved key milestones, including:

Seed to Series D completion.

Attracted new top-level VC firm investment.

Oversubscribed Series B.

First Patients enrolled in Phase 2 Clinical Trial.

Attracted top BOD and SAB expansion with top VC advisors.